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Abstract
Background: Children with Severe Combined Immunodeficiency (SCID) lack autologous T lymphocytes
and present with multiple infections early in infancy. Omenn syndrome is characterized by the sole
emergence of oligoclonal auto-reactive T lymphocytes, resulting in erythroderma and enteropathy.
Omenn syndrome (OS) shares the genetic aetiology of T-B-NK+ SCID, with mutations in RAG1, RAG2, or
DCLRE1C.
Methods: Patients diagnosed with T-B-NK+ SCID or phenotypes suggestive of Omenn syndrome were
investigated by molecular genetic studies using gene tightly linked microsatellite markers followed by direct
sequencing of the coding regions and splice sites of the respective candidate genes.
Results: We report the molecular genetic basis of T-B-NK+ SCID in 22 patients and of OS in seven
patients all of Arab descent from Saudi Arabia. Among the SCID patients, six (from four families) displayed
four homozygous missense mutations in RAG1 including V433M, R624H, R394W, and R559S. Another
four patients (from three familes) showed 3 novel homozygous RAG2 mutations including K127X, S18X,
and Q4X; all of which predict unique premature truncations of RAG2 protein. Among Omenn patients,
four (from two families) have S401P and R396H mutations in RAG1, and a fifth patient has a novel I444M
mutation in RAG2. Seven other patients (six SCID and one OS) showed a gross deletion in exons 1-3 in
DCLRE1C. Altogether, mutations in RAG1/2 and DCLRE1C account for around 50% and 25%, respectively,
in our study cohort, a proportion much higher than in previous reported series. Seven (24%) patients lack
a known genetic aetiology, strongly suggesting that they carry mutations in novel genes associated with
SCID and Omenn disorders that are yet to be discovered in the Saudi population.
Conclusion: Mutation-free patients who lack a known genetic aetiology are likely to carry mutations in
the regulatory elements in the SCID-causing genes or in novel genes that are yet to be discovered. Our
efforts are underway to investigate this possibility by applying the whole genome scans on these cases via
the use of Affymetrix high density DNA SNP chips in addition to homozygosity mapping.
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Background
Severe Combined Immunodeficiency (SCID) is character-
ized by a block in T lymphocyte differentiation that is var-
iably associated with abnormal development of other
lymphocyte lineages, i.e. B or NK lymphocytes or more
rarely of the myeloid lineage [1,2]. The overall SCID fre-
quency is estimated to be 1 in 75,000-100,000 of live
births [3,4]. The clinical presentation is fairly uniform and
is characterized by early onset and diverse infections. Oral
candidiasis, persistent diarrhea with growth impairment
and/or interstitial pneumonitis are the most frequent
infectious manifestations leading to diagnosis [5].
SCID is charecterized by high level of genetic and clinical
heterogeniety, as more than 10 conditions have been
identified and can be distinguished according to cellular
phenotype, inheritance pattern, and the responsible genes
[6-12]. Infants with autosomal recessive SCID caused by
mutations in recombination activating genes 1&2 (RAG1
&RAG2) [13] that are necessary for the somatic rearrange-
ment of antigen receptor genes on T- and B-lymphocytes
[14,15], or in DCLRE1C (Artemis) [16], resemble all other
forms of SCID in their infection susceptibility, however
their lymphocyte phenotype is charecterized by predomi-
nantly circulating NK cells and undetectable B or T lym-
phocytes (T-B-NK+  SCID) [13]. RAG1,  RAG2, and
DCLRE1C are the primary genes responsible for the T-B-
NK+ SCID phenotype [17] and in a recent report, muta-
tions in LIG4 were also documented in patients with this
phenotype who also have microcephaly and developmen-
tal delay [18].
In addition to causing the SCID phenotype, hypomorphic
mutations in RAG1 or RAG2 can lead to partially impaired
V(D)J recombinational activity resulting in Omenn syn-
drome (OS) [19,20]. OS can also result from defects in
other genes including DCLRE1C [21], LIG4 [22], IL7RA
[23], common gamma chain [24], ADA [25], RMRP [26]
and CHD7 [27]. In OS, the absolute lymphocyte count is
elevated due to circulating non-functional oligoclonal T
lymphocytes [28,29]. There is also a third group of
patients, called "atypical SCID/OS" or "leaky SCID"
patients because the clinical features do not exactly match
those of the previous two categories of patients [5].
A high number of patients bearing mutations in RAG
genes has been reported so far (RAGbases are freely acces-
sible on the web at http://www.uta.fi/imt/bioinfo/
RAG1base and http://www.uta.fi/imt/bioinfo/
RAG2base). Various mutations have been identified, both
in RAG1 and RAG2, which can be either severe, leading to
null alleles, or mild, leading to hypomorphic alleles that
can still maintain a residual enzymatic activity. Null
mutants typically predominate in classical T-B- SCID, as
no productive rearrangement of the T cell receptor (TCR)
or B-cell receptor (BCR) can occur, while missense muta-
tions predominate in OS and leaky SCID [30].
The same mutation in different individuals usually lead to
similar phenotype. There are also a few cases in which the
same mutation gives rise to different clinical presentation
[5,19] suggesting that epistasis or other as yet unknown
factors may play a role in determining the clinical picture
and outcome.
Little is known about the molecular aspects of SCID or
Omenn syndrome in Saudi patients. The incidene of SCID
in Saudi population (representative of Arabian popula-
tions) is not well established but an initial data have sug-
gested a 20 fold increase relative to the international
figures [31]. This is mostly due to the high rate of consan-
guinity in the country (56%) [32]. Similar finding can be
also extrapolated from the Iranian registery for primary
immune deficiencies [33]. The underlying molecular
genetic defects responsible for SCID and OS in Saudi pop-
ulation have not been previously studied. In this report,
we document for the first time the molecular findings on
Saudi patients with T-B-NK+ SCID and Omenn syndrome.
Methods
Patients
On the basis of the clinical presentation and the immuno-
logic data the patients were divided into 2 subgroups, T-B-
NK+ SCID and Omenn syndrome. Total of 22 patients
with T-B-NK+ SCID phenotype and seven Omenn syn-
drome patients who have been followed by the immuno-
deficincy clinics at King Faisal Specialist Hospital and
Research Center (KFSHRC) were enrolled in this study.
The clinical and immunological characterestics of all
patients are shown in Additional Files 1 &2. All patients
were screened for mutations in RAG1, RAG2, and
DCLRE1C genes. Patients who are negative for all three
genes were then sequenced for LIG4. This study was
approved by the Institution Review Board (IRB) at
KFSHRC, and an informed consent was obtained for each
of the participating patients.
Cellular and immunological assays
Peripheral leukocyte markers were determined with
immunofluorescence staining and flow cytometry [34]
using labeled antibodies for T cells (CD3, CD4 and CD8),
natural killer cells (CD16 and CD56), and B cells (CD19)
(Antibodies were acquired from Becton, Dickinson & Co,
San Jose, California, USA). T-cell function was determined
in vitro by proliferative responsiveness to phytohemag-
glutinin stimulation as described [35]. Serum Ig levels
were measured by nephelometry [36].
Clinical samples and DNA isolation
For prospective patients, peripheral blood samples were
obtained from the patients and parents through veni-BMC Medical Genetics 2009, 10:116 http://www.biomedcentral.com/1471-2350/10/116
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puncture. Genomic DNA was then extracted from the
blood samples using standard techniques [37]. For patient
who underwent stem cell transplantion before the study
initiation, pretransplant stored DNA was obtained from
the HLA typing laboratory at KFSH&RC for molecular
analysis.
Genotyping by microsatellite markers
Homozygosity mapping based on the utilization of mic-
rosatellite markers flanking RAG1/RAG2  (D11S4203,
D11S4083, and D11S4102) or DCLRE1C  (D10S1725,
D10S191, and D10S1653) was used as a prerequisite for
the whole candidate gene sequencing. Inversely, heterozy-
gosity was used for exclusion of whole gene sequencing.
The rationale for using homozygosity mapping was
because the studied cases in this report were almost exclu-
sively from consanguineous families (patient 19 in Addi-
tional File 1 was the only exception), and hence an
autosomal recessive homozygous founder mutation is
likely to be the cause of the observed phenotype in these
cases. For LIG4, direct sequencing of the coding region of
this gene was implemented without the microsatellite
evaluation; this gene is constituted by 2 exons and only
the second exon is coding. For genotyping, PCR amplifi-
cation was performed on a thermocycler (DNA Engine
Tetrad. MJ Research, USA) in a total volume of 25 μl, con-
taining 10 ng DNA, 50 mM KCl, 10 mM Tris-HCl (pH
9.0), 1.5 mM MgCl2, 0.1% Triton X-100, 0.25 mM of each
dNTP, 0.5 pM of each primer (one fluorescently labeled),
and 1 Unit of Taq polymerase (QIAGEN, D-40724,
Hilden, Germany). Following the assembly of the reaction
mix, PCR was carried out by an initial denaturation step at
95°C for 15 min followed by 30 cycles of denaturation at
95°C for 30 sec, annealing at 50°C for 30 sec and exten-
sion at 72°C for 30 sec followed by a final extension step
at 72°C for 4 min. Amplification products were separated
using a MegaBace 1000 capillary sequencer and sized
using the Genetic Profiler software package (Amersham,
Sunnyvale, CA, USA).
Sequencing of RAG1, RAG2, DCLRE1C, and LIG4
Coding sequences of RAG1, RAG2, DCLRE1C, and LIG4
were amplified from genomic DNA. DNA samples were
obtained before stem cell transplantation of the partici-
pating patients. DNA was also obtained from the parents
when possible. Prior to a full gene sequencing, genotyping
of three markers flanking the above genes was usesd as a
gene exclusion criterion when heterozygosity is estab-
lished. Sequencing primers were designed for the amplifi-
cation of the four genes based on the sequences reported
in databases (RAG1, M29474; RAG2, M94633; DCLRE1C,
NM_022487; LIG4, NM_0002312). Sequencing primers
were designed and optimized for the entire coding region
of each of the three genes. Primer sequences and PCR con-
ditions are available from the authors upon request. PCR
amplifications were performed in 25 μl reactions as previ-
ously described [38]. PCR products were sequenced
directly using the DYEnamic ET Dye Terminator Cycle
Sequencing Kit (Amersham Biosciences; Piscataway, NJ,
USA; http://www.amersham.com) on a MegaBACE 1000
DNA Analysis System (Molecular Dynamics; Sunnyvale,
CA, USA). Sequence data were aligned against the refer-
ence GenBank sequences and examined for variation. For
novel mutation verification, anonymized 96 DNA sam-
ples derived from normal Saudi blood donors were
sequenced.
Results
Patient clinical and immunological characteristics
T-B-NK+ SCID phenotype
Twenty two patients belong to this category were identi-
fied and recruited. They presented with the typical clinical
manifestations including chronic diarrhea, failure to
thrive, severe opportunistic infections, lymphopenia,
absent or reducded T- and B-lymphocytes, hypogamma-
globulinemia, and poor lympohocytes response to
mitogen stimulation (Additional File 1).
Omenn phenotype
Seven patients were identified with the typical clinical
presentation of diffuse exfoliative erythroderma, chronic
diarrhea, failure to thrive, severe opportunistic infections,
generalized lymphadenopathy, and hepatosplenomegaly.
They had detectable activated T-lymphocytes with low cir-
culating B-lymphocytes and no evidence of maternal T-
cell engrafment as indicated by the short tandem repeat
(STR) analysis, hypogammaglobulinemia, and poor lym-
pohocytes response to mitogen stimulation (Additional
File 2). None of our patients had microcephaly or severe
developmental delay.
The overwhelming majority of these patients 28/29
(97%) belong to consanguineous parents all of which
were of Saudi decent. None of our patients had a family
history typical of X-linked inheritance although this could
not be definitely ruled out in other Saudi families where
the affected individuals are only males.
Genotyping of OS and T-B-NK+ SCID patients
RAG1/2 locus genotyping was performed by using a set of
three microsatellite markers (D11S4203, D11S4083, and
D11S4102) spaning a ~1 cM interval on chr 11. A second
set ot 3 microsatellite markers (D10S1725, D10S191, and
D10S1653) spanning a 2 cM locus on chr 10 which har-
bors DCLRE1C was also used. 22 patients with the T-B-
NK+ SCID phenotype and seven patients with OS were
genotyped by using both marker sets. A gene locus was
considered homozygous if at least the second (central)
marker in each marker set is homozygous; in such
instances the respected gene's whole coding regions wereBMC Medical Genetics 2009, 10:116 http://www.biomedcentral.com/1471-2350/10/116
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subsequently analyzed for mutation by direct sequencing.
From the overall 29 patients, homozygosity was demon-
strated in 19 for the RAG1/2 locus, and in seven for the
DCLRE1C locus. Homozygous RAG1 or RAG2 mutations
were detected (as will be described in the next section)
only in 15 leaving four without a detectable mutation
(mutation-free). One or both parents of these four muta-
tion-free patients were curiously homozygous for the
RAG1/2  locus. All seven patients homozygous for the
DCLRE1C locus subsequently showed a novel gross dele-
tion in DCLRE1C.
Gene sequencing for T-B-NK+ SCID and OS patients
Twenty two patients (P1-P22) (Additional File 1) with T-
B-NK+ were identified and screened for mutation in RAG1,
RAG2, and DCLRE1C. Patients who did not show pres-
ence of mutation in any of these three genes were subse-
quently screened for mutation in LIG4  by direct gene
sequencing. Ten patients were positively identified with
homozygous mutations in RAG1/2 (Additional File 3).
Among them, six (from four families) have four different
missense mutations in RAG1. The remaining four positive
patients (from three familes) have three novel
homozygous RAG2 nonsense mutations.
Parents of all ten patients with RAG1 or RAG2 mutations
were confirmned as carriers (heterozygous) of the respec-
tive mutation. Six patients showed a novel gross deletion
mutation spanning exons 1-3 in DCLRE1C. No mutation
was detected in the coding regions of RAG1, RAG2  or
DCLRE1C genes for any of the remaining 6 T-B-NK+ SCID
patients (P16-P21; ~27%).
Five families with Omenn syndrome (OS) that include
seven affected patients (OS1-OS7) were also studied
(Additional File 2). Variable homozygous mutations,
including one novel, were identified in all families except
one (F2) (Additional File 4); no mutation in RAG1, RAG2,
or DCLRE1C was found in OS3 (F2) patient. OS7 (F5)
patient showed the presence of the three-exon deletion in
DCLRE1C that was also seen previously in the T-B-NK+
SCID patients. Parents of the patients with positive RAG1
and RAG2 mutations were confirmned as carriers of the
respective mutation.
Discussion
In this communication, we are reporting the molecular
characterization of a cohort of 29 Saudi patients, 22 of
which are of the T-B-NK+ SCID phenotype and seven with
Omenn syndrome. Although the underlying molecular
causes of T-B-NK+ SCID and Omenn syndrome are well
established world-wide, the aetiology of these disorders is
yet to be defined in Saudi population.
Within the 22 T-B-NK+ SCID patients, ten (46%) were
found to carry homozygous mutations in RAG1 or RAG2,
and six (27%) in DCLRE1C. The remaining six patients
(27%) had no detectable mutation in the coding regions
of RAG1, RAG2, or DCLRE1C. None of those patients were
tested for radiosensitivity to exclude the recently described
causes of T-B-NK+ SCID such as Cernunnos [39] or DNA-
PK deficiency [40]; the lack of growth retardation and
microcephaly, however, argues against Cernunnos defi-
ciency but does not exclusively rule out the involvement
of either of these 2 genes.
Out of 6 RAG1  mutations identified, four proviously
reported (R396H, R394W, S401P and V433M), are inter-
estingly localized within the nonamer binding domain
(NBD) which is constituted of a 56 amino acid strech
between residues 392-447 in the encoded 1040-aa RAG1
protein http://www.expasy.org/uniprot/P15918. R394W
and R396H are critically present within the highly-con-
served N-terminus amino acids 392-396 of the NBD
which is composed of 5 unique residues
(392G393G394R395P396R). The resulting non-conserved
amino acid substitutions within this conserved domain
will most likely result in profound loss of function of
RAG1, and hence abrogation of the protein's interaction
with the recombination signal sequence (RSS) during cel-
lular DNA recombination. This notion is supported by the
severly reduced number of circulating T- and B-lym-
phocytes in these patients combined with a severe reduc-
tion in Ig levels (Additional Files 1 &2). Furthermore,
previous reports also suggested mutations of the basic res-
idues in this conserved domain had led to complete loss
of RAG1 function as demonstrated by inability of the
NBD-mutated RAG1 to mediate V(D)J recombination
[41-43]. The fifth RAG1 mutation, R559S, on the other
hand is localized to the catalytic domain of RAG1 which
interact with RAG2. R559S is a destructive non-conserva-
tive change from large size and basic (R) to small size and
polar (S) amino acid, a change that is likely to disturb the
conformational structure of RAG1 as a consequence, and
hence abrogation of its ability to mediate V(D)J recombi-
nation. This speculation is indeed supported by a previous
report describing the same mutation (R559S) to be asso-
ciated with a reduced ability to mediate V(D)J recombina-
tion [44]. Similar to R559S, R624H is also a non-
conservative change from large size and basic (R) to
medium size and polar (H) amino acid. This change is
also likely to disturb the structure of RAG1 because of the
mutation's critical location in the RAG2-interacting core
region. R624H among other mutations located in the core
region of RAG1 were shown to result in a dramatic reduc-
tion in the mutant RAG1 recombination frequencies com-
pared to the wild-type RAG1 [19].
RAG2 mutations (Q4X, S18X, and K127X) found in the T-
B-NK+ SCID patients were very intreguing since all of them
were of the early truncation type. Even if the mutatnt tran-
scripts escape the nonsense-mediated mRNA decayBMC Medical Genetics 2009, 10:116 http://www.biomedcentral.com/1471-2350/10/116
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(NMD), the protein they encode would be missing the key
RAG2 domains, including the active core within which
lies the nuclear localization signal (NLS). Therefore, the
associated phenotype in the patients with these trunca-
tion mutations is most probably a reflection of a failed
RAG1-RAG2 interaction which occurs normally in the
nucleus, and is required during T-cell receptor (TCR) and
B-cell immunoglobulin (Ig) rearrangements [5,28]. The
fourth RAG2 missense mutation, I444M, was detected in
one patient (OS6). As shown in Additional File 2, this
patient has only a marginal total lymphocyte count (620/
mm3), and thus the patient may have a residual RAG2
activity. This is an appealing proposal because both I&M
amino acids are of similar physico-chemical properties,
and both are medium size and hydrophobic. This muta-
tion is probably of the hypomorphic type which is con-
sistant with the mild phenotype seen in this patient.
Previous reports have revealed that truncated core pro-
teins, encompassing amino acids 384-1008 for RAG1 and
amino acids 1-387 for RAG2, are necessary and sufficient
to rearrange artificial V(D)J recombination substrates in
vitro [45,46]. Our study has identified 8 homozygous
missense and 3 truncation mutations (Additional Files 3
&4) that all map to the RAG1 and RAG2 core regions. In
case of the DCLRE1C three-exon deletion (exons 1-3) that
we identified in seven affected patients (six T-B-NK+ SCID
and one OS), it is anticipated that such mutaion will lead
to a non-functional truncated protein product (provided
the intact exons 4-14 are transcribed and translated).
Unfortuanately, further molecular investigation is not
possible because this is a retrospective study and these
patients had already received bone marrow transplanta-
tion. Interestingly however is that this mutation is capable
of producing either SCID or OS phenotypes, as seen in our
patients.
In correlating genotype to phenotype, it is clear that all
RAG1 and RAG2 mutations reported here, with the excep-
tion of I444M in OS2, are also associated with severe
SCID or OS. Additionally, it is also noteworthy that all our
patients who are negative for mutations in RAG1, RAG2,
or DCLRE1C were also negative for LIG4 indicating that
mutations in the latter are not a common cause of SCID
or OS in Saudi patients. This is consistant with data
reported previously in other populations [5]. Genotyping
and sequencing results for cases in which multiple tribe-
specific  RAG1/2  mutations were detected excluded the
common founder hypothesis for this subset of patients;
however the DCLRE1C 3-exon deletion detected in several
other patients form different families may either be a
recurrent or a founder one and remains open for further
exploration.
Conclusion
This study shows that mutations in RAG1/2 and DCLRE1C
are seen in different Saudi patients with SCID or OS phe-
notype. Given the observed level of consanguinity which
approaches 100% we believe that genomewide homozy-
gosity mapping is likely to reveal novel loci associated
with these phenotypes in the mutation-free patients for
whom linkage to the above 3 loci has been excluded and
this is being actively pursued by our group.
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